{"id":2867850,"date":"2021-09-23T17:00:00","date_gmt":"2021-09-23T21:00:00","guid":{"rendered":"https:\/\/www.merck.com\/?post_type=news_item&#038;p=2867850"},"modified":"2021-09-24T10:27:49","modified_gmt":"2021-09-24T14:27:49","slug":"merck-announces-settlement-and-license-agreement-resolving-pneumococcal-conjugate-vaccine-patent-litigation","status":"publish","type":"news_item","link":"https:\/\/www.merck.com\/news\/merck-announces-settlement-and-license-agreement-resolving-pneumococcal-conjugate-vaccine-patent-litigation\/","title":{"rendered":"Merck Announces Settlement and License Agreement Resolving Pneumococcal Conjugate Vaccine Patent Litigation"},"content":{"rendered":"\n<p>KENILWORTH, N.J., Sept. 23, 2021 \u2013 Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today it&nbsp; has entered into a settlement and license agreement with Pfizer Inc., resolving all worldwide patent infringement litigation related to the use of Merck\u2019s investigational and licensed pneumococcal conjugate vaccine (PCV) products, including VAXNEUVANCE<sup>TM<\/sup> (Pneumococcal 15-valent Conjugate Vaccine).&nbsp;<\/p>\n\n\n\n<p>Under the terms of the agreement Merck will make certain regulatory milestone payments to Pfizer, as well as royalty payments on the worldwide sales of its PCV products as follows:<\/p>\n\n\n\n<ul><li>7.25% of net sales of all Merck PCV products through and including Dec. 31, 2026.<\/li><li>2.5% of net sales of all Merck PCV products from Jan. 1, 2027 through and including Dec. 31, 2035.<\/li><\/ul>\n\n\n\n<p><strong>About VAXNEUVANCE<\/strong><\/p>\n\n\n\n<p>VAXNEUVANCE is indicated for active immunization for the prevention of invasive disease caused by\u00a0Streptococcus pneumoniae\u00a0serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults 18 years of age and older.\u00a0<\/p>\n\n\n\n<p><strong>Select Safety Information<\/strong><\/p>\n\n\n\n<p>Do not administer VAXNEUVANCE to individuals with a severe allergic reaction (e.g., anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.<\/p>\n\n\n\n<p>Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.<\/p>\n\n\n\n<p>The most commonly reported solicited adverse reactions in individuals 18 through 49 years of age were: injection site pain (75.8%), fatigue (34.3%), myalgia (28.8%), headache (26.5%), injection site swelling (21.7%), injection site erythema (15.1%) and arthralgia (12.7%).<\/p>\n\n\n\n<p>The most commonly reported solicited adverse reactions in individuals 50 years of age and older were: injection site pain (66.8%), myalgia (26.9%), fatigue (21.5%), headache (18.9%), injection site swelling (15.4%), injection site erythema (10.9%) and arthralgia (7.7%).<\/p>\n\n\n\n<p>Vaccination with VAXNEUVANCE may not protect all vaccine recipients.<\/p>\n\n\n\n<p><strong>About Merck<\/strong><\/p>\n\n\n\n<p>For over 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world\u2019s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals \u2013 including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases \u2013 as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit <a href=\"http:\/\/www.merck.com\">www.merck.com<\/a> and connect with us on <a href=\"https:\/\/twitter.com\/Merck\" target=\"_blank\" rel=\"noreferrer noopener\">Twitter<\/a>, <a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" target=\"_blank\" rel=\"noreferrer noopener\">Facebook<\/a>, <a href=\"https:\/\/www.instagram.com\/merck\/\" target=\"_blank\" rel=\"noreferrer noopener\">Instagram<\/a>, <a href=\"http:\/\/www.youtube.com\/Merck\" target=\"_blank\" rel=\"noreferrer noopener\">YouTube<\/a> and <a href=\"https:\/\/www.linkedin.com\/company\/merck\" target=\"_blank\" rel=\"noreferrer noopener\">LinkedIn<\/a>.<\/p>\n\n\n\n<p><strong>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/strong><\/p>\n\n\n\n<p>This statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company\u2019s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.<\/p>\n\n\n\n<p>Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company\u2019s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company\u2019s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and\/or regulatory actions.<\/p>\n\n\n\n<p>The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company\u2019s 2020 Annual Report on Form 10-K and the company\u2019s other filings with the Securities and Exchange Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/www.sec.gov\/\" target=\"_blank\" rel=\"noreferrer noopener\">www.sec.gov<\/a>).<\/p>\n\n\n\n<p><strong>Please see Prescribing Information for VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) at <a href=\"https:\/\/www.merck.com\/product\/usa\/pi_circulars\/v\/vaxneuvance\/vaxneuvance_pi.pdf\">https:\/\/www.merck.com\/product\/usa\/pi_circulars\/v\/vaxneuvance\/vaxneuvance_pi.pdf<\/a> and Patient Information at <a href=\"https:\/\/www.merck.com\/product\/usa\/pi_circulars\/v\/vaxneuvance\/vaxneuvance_ppi.pdf\">https:\/\/www.merck.com\/product\/usa\/pi_circulars\/v\/vaxneuvance\/vaxneuvance_ppi.pdf<\/a>.<\/strong><\/p>\n\n\n\n<p class=\"has-text-align-center\">###<\/p>\n\n\n\n<p><strong>Media Contacts:<\/strong><\/p>\n\n\n\n<p>Melissa Moody 215-407-3536<\/p>\n\n\n\n<p>Steve Wanczyk 267-305-5563<\/p>\n\n\n\n<p id=\"block-00f8e72d-2fcd-4227-9271-eb16d6ac3a10\"><strong>Investor Contacts:<\/strong><\/p>\n\n\n\n<p id=\"block-42a895b2-6bef-469d-8f55-1a3f9ef3aaac\">Peter Dannenbaum 908-740-1037<\/p>\n\n\n\n<p>Raychel Kruper 908-740-2107<\/p>\n","protected":false},"excerpt":{"rendered":"<p>KENILWORTH, N.J., Sept. 23, 2021 \u2013 Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today it&nbsp; has entered into a settlement and license agreement with Pfizer Inc., resolving all worldwide patent infringement litigation related to the use of Merck\u2019s investigational and licensed pneumococcal conjugate vaccine (PCV) products, including VAXNEUVANCETM (Pneumococcal 15-valent [&hellip;]<\/p>\n","protected":false},"template":"","meta":{"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"episode_type":"","audio_file":"","duration":"","filesize":"","date_recorded":"","explicit":"","block":"","filesize_raw":""},"tags":[290],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v18.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Merck Announces Settlement and License Agreement Resolving Pneumococcal Conjugate Vaccine Patent Litigation - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.merck.com\/news\/merck-announces-settlement-and-license-agreement-resolving-pneumococcal-conjugate-vaccine-patent-litigation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Settlement and License Agreement Resolving Pneumococcal Conjugate Vaccine Patent Litigation - Merck.com\" \/>\n<meta property=\"og:description\" content=\"KENILWORTH, N.J., Sept. 23, 2021 \u2013 Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today it&nbsp; has entered into a settlement and license agreement with Pfizer Inc., resolving all worldwide patent infringement litigation related to the use of Merck\u2019s investigational and licensed pneumococcal conjugate vaccine (PCV) products, including VAXNEUVANCETM (Pneumococcal 15-valent [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.merck.com\/news\/merck-announces-settlement-and-license-agreement-resolving-pneumococcal-conjugate-vaccine-patent-litigation\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2021-09-24T14:27:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.merck.com\/wp-content\/uploads\/sites\/5\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.merck.com\/#website\",\"url\":\"https:\/\/www.merck.com\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.merck.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.merck.com\/news\/merck-announces-settlement-and-license-agreement-resolving-pneumococcal-conjugate-vaccine-patent-litigation\/#webpage\",\"url\":\"https:\/\/www.merck.com\/news\/merck-announces-settlement-and-license-agreement-resolving-pneumococcal-conjugate-vaccine-patent-litigation\/\",\"name\":\"Merck Announces Settlement and License Agreement Resolving Pneumococcal Conjugate Vaccine Patent Litigation - Merck.com\",\"isPartOf\":{\"@id\":\"https:\/\/www.merck.com\/#website\"},\"datePublished\":\"2021-09-23T21:00:00+00:00\",\"dateModified\":\"2021-09-24T14:27:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.merck.com\/news\/merck-announces-settlement-and-license-agreement-resolving-pneumococcal-conjugate-vaccine-patent-litigation\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.merck.com\/news\/merck-announces-settlement-and-license-agreement-resolving-pneumococcal-conjugate-vaccine-patent-litigation\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.merck.com\/news\/merck-announces-settlement-and-license-agreement-resolving-pneumococcal-conjugate-vaccine-patent-litigation\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\/\/www.merck.com\/news-archive\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Settlement and License Agreement Resolving Pneumococcal Conjugate Vaccine Patent Litigation\"}]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Settlement and License Agreement Resolving Pneumococcal Conjugate Vaccine Patent Litigation - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.merck.com\/news\/merck-announces-settlement-and-license-agreement-resolving-pneumococcal-conjugate-vaccine-patent-litigation\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Settlement and License Agreement Resolving Pneumococcal Conjugate Vaccine Patent Litigation - Merck.com","og_description":"KENILWORTH, N.J., Sept. 23, 2021 \u2013 Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today it&nbsp; has entered into a settlement and license agreement with Pfizer Inc., resolving all worldwide patent infringement litigation related to the use of Merck\u2019s investigational and licensed pneumococcal conjugate vaccine (PCV) products, including VAXNEUVANCETM (Pneumococcal 15-valent [&hellip;]","og_url":"https:\/\/www.merck.com\/news\/merck-announces-settlement-and-license-agreement-resolving-pneumococcal-conjugate-vaccine-patent-litigation\/","og_site_name":"Merck.com","article_modified_time":"2021-09-24T14:27:49+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/www.merck.com\/wp-content\/uploads\/sites\/5\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebSite","@id":"https:\/\/www.merck.com\/#website","url":"https:\/\/www.merck.com\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.merck.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.merck.com\/news\/merck-announces-settlement-and-license-agreement-resolving-pneumococcal-conjugate-vaccine-patent-litigation\/#webpage","url":"https:\/\/www.merck.com\/news\/merck-announces-settlement-and-license-agreement-resolving-pneumococcal-conjugate-vaccine-patent-litigation\/","name":"Merck Announces Settlement and License Agreement Resolving Pneumococcal Conjugate Vaccine Patent Litigation - Merck.com","isPartOf":{"@id":"https:\/\/www.merck.com\/#website"},"datePublished":"2021-09-23T21:00:00+00:00","dateModified":"2021-09-24T14:27:49+00:00","breadcrumb":{"@id":"https:\/\/www.merck.com\/news\/merck-announces-settlement-and-license-agreement-resolving-pneumococcal-conjugate-vaccine-patent-litigation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.merck.com\/news\/merck-announces-settlement-and-license-agreement-resolving-pneumococcal-conjugate-vaccine-patent-litigation\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.merck.com\/news\/merck-announces-settlement-and-license-agreement-resolving-pneumococcal-conjugate-vaccine-patent-litigation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/www.merck.com\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Settlement and License Agreement Resolving Pneumococcal Conjugate Vaccine Patent Litigation"}]}]}},"_links":{"self":[{"href":"https:\/\/www.merck.com\/wp-json\/wp\/v2\/news_item\/2867850"}],"collection":[{"href":"https:\/\/www.merck.com\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/www.merck.com\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":2,"href":"https:\/\/www.merck.com\/wp-json\/wp\/v2\/news_item\/2867850\/revisions"}],"predecessor-version":[{"id":2870501,"href":"https:\/\/www.merck.com\/wp-json\/wp\/v2\/news_item\/2867850\/revisions\/2870501"}],"wp:attachment":[{"href":"https:\/\/www.merck.com\/wp-json\/wp\/v2\/media?parent=2867850"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.merck.com\/wp-json\/wp\/v2\/tags?post=2867850"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}